Gossamer Bio Overview
Valuation check: GOSS's ROE is 133.17%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow133.17%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Gossamer Bio (GOSS) currently reports a ROE of 133.17%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Gossamer Bio's ROE history and peer comparisons.
Gossamer Bio's ROE of 133.17% is higher than the Healthcare sector average of -100.59%. That is roughly 232.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Gossamer Bio's current 133.17% should be judged against Healthcare norms (sector average: -100.59%) and against GOSS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 133.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Gossamer Bio, and consider following GOSS for alerts when major investors trade the stock.
Gossamer Bio is classified in the Healthcare sector. On ROE, it currently shows 133.17% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GOSS with unrelated industries.
